Our first test for uveal melanoma, a rare and deadly eye cancer, is used to identify those at high risk for metastasis. With demonstrated improved accuracy over existing staging and prognostic tools, the test has become the standard of care for uveal melanoma and has successfully secured reimbursement. We are using its innovation as a model for our growing lineup of practice-changing tests, including our newer cutaneous (skin) melanoma prognostic assay. We have active development programs for assays in several other underserved cancers.
Castle Biosciences’ tests are performed in a CLIA-certified, CAP-accredited clinical laboratory.
Gross profit (Q2, 2020)
Gross profit margin (Q2, 2020), %
Net income (Q2, 2020)
EBIT (Q2, 2020)
Market capitalization (23-Sept-2020)
Closing stock price (23-Sept-2020)
Castle Biosciences has 216 Twitter Followers. The number of followers has increased 3.2% month over month and increased 11.1% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Castle Biosciences founded?
Castle Biosciences was founded in 2008.
Who are Castle Biosciences key executives?
Castle Biosciences's key executives are Derek Maetzold, Bernhard E. Spiess and Federico Monzon.
How many employees does Castle Biosciences have?
Castle Biosciences has 91 employees.
What is Castle Biosciences revenue?
Latest Castle Biosciences annual revenue is $51.9 m.
What is Castle Biosciences revenue per employee?
Latest Castle Biosciences revenue per employee is $569.9 k.
Who are Castle Biosciences competitors?
Competitors of Castle Biosciences include Biodesy, Laboratory Corporation of America Holdings and Astute Medical.
Where is Castle Biosciences headquarters?
Castle Biosciences headquarters is located at 820 S Friendswood Dr #201, Friendswood.
Where are Castle Biosciences offices?
Castle Biosciences has offices in Friendswood and Phoenix.
How many offices does Castle Biosciences have?
Castle Biosciences has 2 offices.
Receive alerts for 300+ data fields across thousands of companies